Page last updated: 2024-12-06
rogletimide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 56487 |
CHEMBL ID | 289116 |
SCHEMBL ID | 4281 |
MeSH ID | M0142608 |
Synonyms (42)
Synonym |
---|
nsc619778 |
nsc-619778 |
pyridoglutethimide |
NCI60_005808 |
rogletimide |
121840-95-7 |
D05746 |
rogletimide (usan/inn) |
2,6-piperidinedione, 3-ethyl-3-(4-pyridinyl)- |
(+-)-pyridoglutethimide |
racemic-pyridoglutethimide |
2-ethyl-2-(4-pyridyl)glutarimide |
3-pyg |
3-ethyl-3-(4-pyridyl)piperidine-2,6-dione |
92788-10-8 |
CHEMBL289116 , |
3-ethyl-4,5-dihydro-3h-[3,4'']bipyridinyl-2,6-dione |
3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione |
bdbm50015985 |
rogletimide [usan:inn:ban] |
14p4qr28qf , |
unii-14p4qr28qf |
3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione |
AM20050714 |
AKOS015904738 |
2,6-piperidinedione, 3-ethyl-3-(4-pyridinyl)-, (+/-)- |
rogletimide [who-dd] |
rogletimide [mart.] |
rogletimide [usan] |
(+/-)-2-ethyl-2-(4-pyridyl)glutarimide |
rogletimide [inn] |
(+/-)-pyridoglutethimide |
SCHEMBL4281 |
(+/-) 3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione |
3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione |
FT-0749860 |
QXKJWHWUDVQATH-UHFFFAOYSA-N |
3-ethyl-3-(4-pyridyl)-2,6-piperidinedione |
3-aminomethyl-biphenyl-4-ylamine |
Q7359418 |
pyridoglutethimide; racemic pyridoglutethimide |
DTXSID60869670 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" This report gives the results of a detailed pharmacokinetic and endocrine study of PyG in ten patients." | ( Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Coombes, RC; Dowsett, M; Haynes, B; Jarman, M; Jones, A; Lonning, P; MacNeill, F; Mehta, A; Newton, C; Powles, TJ, 1991) | 0.28 |
" This study investigates the pharmacokinetics of pyridoglutethimide in the rat and the rabbit: the plasma half-life is 6 hr in the rat and 16." | ( Pyridoglutethimide [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione], an analogue of aminoglutethimide. Metabolism and pharmacokinetics. Goss, PE; Griggs, LJ; Jarman, M; Seago, A, 1986) | 0.27 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" On subsequent repeated dosing with PyG, both the Km (4." | ( Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Coombes, RC; Dowsett, M; Griggs, LJ; Haynes, BP; Jarman, M; Jones, A; Lønning, PE; Mehta, A; Powles, T; Stein, R, 1991) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Aromatase | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0000 | 1.2904 | 10.0000 | AID53546; AID53574; AID53575 |
Aromatase | Homo sapiens (human) | Ki | 5.4000 | 0.0000 | 0.6046 | 9.5010 | AID53888; AID53889; AID54049 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Other Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Aromatase | Homo sapiens (human) | Ka app | 0.2800 | 0.1300 | 0.2050 | 0.2800 | AID54046 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (15)
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of chronic inflammatory response | Aromatase | Homo sapiens (human) |
steroid biosynthetic process | Aromatase | Homo sapiens (human) |
estrogen biosynthetic process | Aromatase | Homo sapiens (human) |
androgen catabolic process | Aromatase | Homo sapiens (human) |
syncytium formation | Aromatase | Homo sapiens (human) |
negative regulation of macrophage chemotaxis | Aromatase | Homo sapiens (human) |
sterol metabolic process | Aromatase | Homo sapiens (human) |
female genitalia development | Aromatase | Homo sapiens (human) |
mammary gland development | Aromatase | Homo sapiens (human) |
uterus development | Aromatase | Homo sapiens (human) |
prostate gland growth | Aromatase | Homo sapiens (human) |
testosterone biosynthetic process | Aromatase | Homo sapiens (human) |
positive regulation of estradiol secretion | Aromatase | Homo sapiens (human) |
female gonad development | Aromatase | Homo sapiens (human) |
response to estradiol | Aromatase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Molecular Functions (7)
Process | via Protein(s) | Taxonomy |
---|---|---|
iron ion binding | Aromatase | Homo sapiens (human) |
steroid hydroxylase activity | Aromatase | Homo sapiens (human) |
electron transfer activity | Aromatase | Homo sapiens (human) |
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | Aromatase | Homo sapiens (human) |
oxygen binding | Aromatase | Homo sapiens (human) |
heme binding | Aromatase | Homo sapiens (human) |
aromatase activity | Aromatase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Ceullar Components (3)
Process | via Protein(s) | Taxonomy |
---|---|---|
endoplasmic reticulum | Aromatase | Homo sapiens (human) |
endoplasmic reticulum membrane | Aromatase | Homo sapiens (human) |
membrane | Aromatase | Homo sapiens (human) |
endoplasmic reticulum | Aromatase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Bioassays (11)
Research
Studies (19)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (15.79) | 18.7374 |
1990's | 15 (78.95) | 18.2507 |
2000's | 1 (5.26) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.33
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.33) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (4.76%) | 5.53% |
Reviews | 4 (19.05%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (76.19%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |